| pubmed-article:9452275 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9452275 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9452275 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:9452275 | lifeskim:mentions | umls-concept:C0280100 | lld:lifeskim |
| pubmed-article:9452275 | lifeskim:mentions | umls-concept:C0020823 | lld:lifeskim |
| pubmed-article:9452275 | lifeskim:mentions | umls-concept:C0144576 | lld:lifeskim |
| pubmed-article:9452275 | lifeskim:mentions | umls-concept:C1521761 | lld:lifeskim |
| pubmed-article:9452275 | lifeskim:mentions | umls-concept:C1948023 | lld:lifeskim |
| pubmed-article:9452275 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:9452275 | lifeskim:mentions | umls-concept:C0205269 | lld:lifeskim |
| pubmed-article:9452275 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:9452275 | pubmed:dateCreated | 1998-2-19 | lld:pubmed |
| pubmed-article:9452275 | pubmed:abstractText | Ifosfamide and paclitaxel are antineoplastic agents with broad activity and with different mechanisms of action. A Phase I trial was conducted to determine the maximum tolerated dose and associated toxicities of these agents when used in combination. | lld:pubmed |
| pubmed-article:9452275 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9452275 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9452275 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:9452275 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9452275 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9452275 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9452275 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9452275 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9452275 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:9452275 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:9452275 | pubmed:author | pubmed-author:ThompsonLL | lld:pubmed |
| pubmed-article:9452275 | pubmed:author | pubmed-author:MutoMM | lld:pubmed |
| pubmed-article:9452275 | pubmed:author | pubmed-author:BerkowitzRR | lld:pubmed |
| pubmed-article:9452275 | pubmed:author | pubmed-author:ShulmanL NLN | lld:pubmed |
| pubmed-article:9452275 | pubmed:author | pubmed-author:BuswellLL | lld:pubmed |
| pubmed-article:9452275 | pubmed:author | pubmed-author:SheetsEE | lld:pubmed |
| pubmed-article:9452275 | pubmed:author | pubmed-author:BunnellC ACA | lld:pubmed |
| pubmed-article:9452275 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9452275 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:9452275 | pubmed:volume | 82 | lld:pubmed |
| pubmed-article:9452275 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9452275 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9452275 | pubmed:pagination | 561-6 | lld:pubmed |
| pubmed-article:9452275 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9452275 | pubmed:meshHeading | pubmed-meshheading:9452275-... | lld:pubmed |
| pubmed-article:9452275 | pubmed:meshHeading | pubmed-meshheading:9452275-... | lld:pubmed |
| pubmed-article:9452275 | pubmed:meshHeading | pubmed-meshheading:9452275-... | lld:pubmed |
| pubmed-article:9452275 | pubmed:meshHeading | pubmed-meshheading:9452275-... | lld:pubmed |
| pubmed-article:9452275 | pubmed:meshHeading | pubmed-meshheading:9452275-... | lld:pubmed |
| pubmed-article:9452275 | pubmed:meshHeading | pubmed-meshheading:9452275-... | lld:pubmed |
| pubmed-article:9452275 | pubmed:meshHeading | pubmed-meshheading:9452275-... | lld:pubmed |
| pubmed-article:9452275 | pubmed:meshHeading | pubmed-meshheading:9452275-... | lld:pubmed |
| pubmed-article:9452275 | pubmed:meshHeading | pubmed-meshheading:9452275-... | lld:pubmed |
| pubmed-article:9452275 | pubmed:meshHeading | pubmed-meshheading:9452275-... | lld:pubmed |
| pubmed-article:9452275 | pubmed:meshHeading | pubmed-meshheading:9452275-... | lld:pubmed |
| pubmed-article:9452275 | pubmed:meshHeading | pubmed-meshheading:9452275-... | lld:pubmed |
| pubmed-article:9452275 | pubmed:meshHeading | pubmed-meshheading:9452275-... | lld:pubmed |
| pubmed-article:9452275 | pubmed:meshHeading | pubmed-meshheading:9452275-... | lld:pubmed |
| pubmed-article:9452275 | pubmed:meshHeading | pubmed-meshheading:9452275-... | lld:pubmed |
| pubmed-article:9452275 | pubmed:meshHeading | pubmed-meshheading:9452275-... | lld:pubmed |
| pubmed-article:9452275 | pubmed:meshHeading | pubmed-meshheading:9452275-... | lld:pubmed |
| pubmed-article:9452275 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9452275 | pubmed:articleTitle | A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors. | lld:pubmed |
| pubmed-article:9452275 | pubmed:affiliation | Hematology-Oncology Division, Brigham and Women's Hospital, Boston, Massachusetts, USA. | lld:pubmed |
| pubmed-article:9452275 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9452275 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9452275 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:9452275 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9452275 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9452275 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9452275 | lld:pubmed |
